American International Group Inc. Has $9.72 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

American International Group Inc. trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,701 shares of the company’s stock after selling 1,234 shares during the period. American International Group Inc. owned approximately 0.10% of Medpace worth $9,717,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Medpace by 2.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock worth $2,114,000 after buying an additional 148 shares during the period. Portside Wealth Group LLC raised its holdings in Medpace by 14.8% during the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after buying an additional 183 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Medpace by 355.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after buying an additional 2,774 shares during the period. Norden Group LLC raised its holdings in Medpace by 207.8% during the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock worth $1,537,000 after buying an additional 3,385 shares during the period. Finally, Eagle Asset Management Inc. raised its holdings in Medpace by 155.0% during the 4th quarter. Eagle Asset Management Inc. now owns 226,435 shares of the company’s stock worth $69,409,000 after buying an additional 137,632 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the transaction, the chief executive officer now directly owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Medpace news, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the sale, the chief executive officer now owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 3,987 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $395.22, for a total value of $1,575,742.14. Following the sale, the chief executive officer now directly owns 660,351 shares of the company’s stock, valued at approximately $260,983,922.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,621 shares of company stock valued at $11,816,852. 20.30% of the stock is owned by corporate insiders.

Medpace Trading Up 1.8 %

NASDAQ:MEDP opened at $402.99 on Wednesday. Medpace Holdings, Inc. has a 1-year low of $216.87 and a 1-year high of $421.00. The firm has a fifty day simple moving average of $393.75 and a 200 day simple moving average of $361.00. The stock has a market capitalization of $12.48 billion, a PE ratio of 41.08, a P/E/G ratio of 1.95 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million during the quarter, compared to analysts’ expectations of $512.39 million. During the same period last year, the business earned $2.27 earnings per share. The firm’s revenue was up 17.7% on a year-over-year basis. On average, equities analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on MEDP shares. TD Cowen started coverage on shares of Medpace in a report on Wednesday, May 29th. They set a “buy” rating and a $452.00 target price on the stock. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, June 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 price target for the company. Mizuho started coverage on shares of Medpace in a research note on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target for the company. Finally, Robert W. Baird raised their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $443.14.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.